VVOS - Vivos trades higher on new data indicating potential of therapy for sleep disorder

juststock/iStock via Getty Images Vivos Therapeutics (VVOS) has surged ~19.9% on the announcement of new data highlighting the value of the company’s proprietary Vivos treatment targeted at various dental issues linked to obstructive sleep apnea ((OSA)) and other health conditions. The data from the survey conducted by the independent research firm, The EyeDeas Company, relate to Vivos treatment in dental tissue anomalies and dentofacial malformations linked to OSA and other conditions, the company said. According to results from 123 anonymous patients, 97% of them have said that they reached the desired outcome for OSA from Vivos therapy. “This survey reaffirms that patients are in dire need of a solution for their OSA – one that is non-surgical, non-invasive, non-pharmaceutical and low-cost – and that’s exactly the market niche that the Vivos treatment fills,” commented Kirk Huntsman, the company CEO.

For further details see:

Vivos trades higher on new data indicating potential of therapy for sleep disorder